间充质干细胞治疗支气管哮喘的动物实验作用机制研究进展

Advances of mechanism of mesenchymal stem cells in animal experiments with bronchial asthma

支气管哮喘是儿童常见的涉及免疫反应所致的以气道高反应、气道炎症、气道重塑为特征的慢性气道炎症性疾病。目前糖皮质激素和变应原特异性免疫疗法存在一定限制。许多动物实验结果证实,间充质干细胞(MSCs)可通过免疫调节作用减轻哮喘动物模型气道炎症、改善气道高反应、逆转气道重塑。因此,MSCs作为儿童哮喘有效治疗策略,具有很大的应用前景。现就近年来在MSCs治疗哮喘的动物实验作用机制方面取得的进展进行综述,以探讨MSCs治疗哮喘的价值。

Bronchial asthma is a common chronic airway inflammatory disease in children characterized by hyper-responsiveness,airway inflammation,and airway remodeling caused by immune responses.Currently,some limitations of glucocorticoid and allergen-specific immunotherapy restrict their application to asthma treatment.Based on the results of many animal experiments,mesenchymal stem cells(MSCs)are validated to reduce airway inflammation,improve airway hyper-responsiveness,and reverse airway remodeling through immunomodulation.Therefore,it has great application prospects as an effective therapeutic strategy for children with asthma.To explore the value of MSCs in the treatment of asthma,its underlying mechanisms are reviewed in the present study.